Breast Cancer: Drugs
2026-07-06 · Department of Health and Social Care · HL1762 · Official question
Baroness Ritchie of Downpatrick
Question
To ask His Majesty's Government what estimate they have made of the impact of the lack of accessibility of the Enhertu drug for HER2-low metastatic breast cancer in England upon the objective of becoming one of the top three fastest places in Europe for p
Answer
HER2‑low breast cancer is managed with treatments for HER2‑negative breast cancer. The National Institute for Health and Care Excellence (NICE) has published guidance recommending a number of medicines for the treatment of HER2-negative breast cancer whic...